Skip to search formSkip to main contentSkip to account menu

PCSK9 Inhibitors [MoA]

Known as: PCSK9 Inhibitors, Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors 
National Institutes of Health

Related topics

Related topics

5 relations
1 ML alirocumab 75 MG/ML Prefilled Syringe1 ML evolocumab 140 MG/ML Prefilled SyringePCSK9 Inhibitor [EPC]alirocumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Large Clinical Trials of Statin-Associated Muscle Symptoms
The ability to treat dyslipidemia in patients with statin-associated muscle symptoms (SAMS) is a major clinical predicament… 
Review
2019
Review
2019
[PCSK9 inhibitors (PCSK9i), a new opportunity for cardiovascular prevention: clinical and regulatory aspects and access to therapy.]
Elevated levels of LDL-C represent a major risk factor for cardiovascular (CV) disease and recent guidelines recommended early… 
2019
2019
PATIENT ACCESS TO PCSK9 INHIBITORS IS SUCCESSFUL UTILIZING A DEDICATED PROTOCOL AND CARDIOVASCULAR TEAM
2019
2019
Practical guide for the use of PCSK9 inhibitors in Portugal
2017
2017
THE EFFECT OF PCSK9 INHIBITION ON LDL-SUBFRACTIONS IN PATIENTS WITH SEVERE LDL-HYPERCHOLESTEROLEMIA
Review
2016
Review
2016
PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions.
Review
2016
Review
2016
PCSK9-Inhibitoren bei Hypercholesterinämie
ZusammenfassungDer Zusammenhang zwischen Glukose- und Lipidstoffwechsel ist komplex. Von überragender Bedeutung ist dabei die… 
2015
2015
PCSK9 inhibitors – past, present and future
Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) morbidity and mortality. Statins are… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)